Search Results for: HSP90AB1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel PROS1 protein S
  • Platelet degranulation
  • Intrinsic Pathway of Fibrin Clot Formation
  • Common Pathway of Fibrin Clot Formation
  • Gamma-carboxylation of protein precursors
  • Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
  • Removal of aminoterminal propeptides from gamma-carboxylated proteins
  • Cell surface interactions at the vascular wall
  • Regulation of Complement cascade
  • Drotrecogin alfa
  • Menadione
  • Sodium tetradecyl sulfate
  • Kappadione
  • Inherited thrombophilia
Novel PENK proenkephalin
  • Peptide ligand-binding receptors
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (i) signalling events
  • Post-translational protein phosphorylation
Novel CCR7 C-C motif chemokine receptor 7
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
Novel MTX2 metaxin 2
  • Mitochondrial protein import
  • Cristae formation
Novel SLC25A27 solute carrier family 25 member 27
  • The fatty acid cycling model
  • The proton buffering model
Novel GNPDA1 glucosamine-6-phosphate deaminase 1
  • Glycolysis
  • Beta-D-Glucose
  • 2-Deoxy-2-Amino Glucitol-6-Phosphate
  • N-acetyl-D-glucosamine-6-phosphate
Novel TPSAB1 tryptase alpha/beta 1
  • Activation of Matrix Metalloproteinases
  • Amido Phenyl Pyruvic Acid
  • 4-PIPERIDIN-4-YLBUTANAL
  • [4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE
  • 1-(1'-{[3-(methylsulfanyl)-2-benzothiophen-1-yl]carbonyl}spiro[1-benzofuran-3,4'-piperidin]-5-yl)methanamine
  • 1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine
  • JNJ-27390467
Novel CETN3 centrin 3
Novel GPRC5B G protein-coupled receptor class C group 5 member B
Novel ZFP36L2 ZFP36 ring finger protein like 2
TP53 tumor protein p53
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Factors involved in megakaryocyte development and platelet production
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Osteosarcoma
  • Adrenal carcinoma
  • Thyroid cancer
  • Breast cancer
  • Basal cell carcinoma
  • Malignant melanoma
  • Pancreatic cancer
  • Gastric cancer
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Small cell lung cancer
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Glioma
  • Squamous cell carcinoma
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Cancer of the anal canal
  • Hepatocellular carcinoma
  • Choriocarcinoma
  • Vulvar cancer
  • Choroid plexus papilloma
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Hairy-cell leukemia
  • Bladder cancer
  • Chronic lymphocytic leukemia (CLL)
  • Penile cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Colorectal cancer
  • Laryngeal cancer
  • Chronic myeloid leukemia (CML)
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • CTLA4 inhibitory signaling
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
STAT3 signal transducer and activator of transcription 3
  • Interleukin-6 signaling
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signalling to STAT3
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by Leptin
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Association of TriC/CCT with target proteins during biosynthesis
  • Transcriptional regulation of pluripotent stem cells
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Activates STAT3
  • PTK6 Activates STAT3
  • Interleukin-20 family signaling
  • MET activates STAT3
  • MET activates STAT3
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-37 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Transcriptional regulation of granulopoiesis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • ENMD-1198
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
  • Oral cancer
IKBKG inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • SUMOylation of immune response proteins
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • AGRO100
  • Tarenflurbil
  • Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
  • Incontinentia pigmenti
  • Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
CHUK component of inhibitor of nuclear factor kappa B kinase complex
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • AKT phosphorylates targets in the cytosol
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Constitutive Signaling by AKT1 E17K in Cancer
  • NIK-->noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Aminosalicylic acid
  • Mesalazine
  • Sulfasalazine
  • Acetylcysteine
  • Cocoon syndrome
YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • MTOR signalling
  • mTORC1-mediated signalling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • ARMS-mediated activation
  • Signaling by Hippo
  • Rap1 signalling
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • RAF activation
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Regulation of localization of FOXO transcription factors
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • Copper
  • Phenethyl Isothiocyanate
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Mesalazine
  • Sulfasalazine
  • Acetylsalicylic acid
  • Auranofin
  • Arsenic trioxide
  • MLN0415
  • Acetylcysteine
  • Ertiprotafib
  • Fostamatinib
CDKN2A cyclin dependent kinase inhibitor 2A
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Transcriptional Regulation by VENTX
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Apoptotic factor-mediated response
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • Regulation of TP53 Degradation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function
  • Evasion of Oncogene Induced Senescence Due to p14ARF Defects
  • Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects
  • Bladder cancer
  • Type II diabetes mellitus
  • Pancreatic cancer
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Chronic myeloid leukemia (CML)
  • Oral cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Glioma
  • Osteosarcoma
  • Squamous cell carcinoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Malignant islet cell carcinoma
  • Laryngeal cancer
  • Hepatocellular carcinoma
  • Esophageal cancer
  • Malignant melanoma
STAT1 signal transducer and activator of transcription 1
  • Interleukin-6 signaling
  • ISG15 antiviral mechanism
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Regulation of RUNX2 expression and activity
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
  • IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency

Page 1 out of 4 pages